Ya-Qin Zheng, Rui Huang, Wen-Lu Zou, Chao Liu, H. Niu, J. Yue
The prognosis for unresectable locally advanced pancreatic cancer (LAPC) is still poor, and the best therapeutic option is still unknown. The common treatments for LAPC, concurrent chemoradiotherapy (CCRT), 125I seed implantation combined with chemotherapy (125IC), and chemotherapy alone (CA), were studied. In addition, we looked into the impact of radiation dose on the survival of patients receiving chemoradiotherapy.
{"title":"Comparing concurrent chemoradiotherapy, 125I seed implantation combined with chemotherapy, and chemotherapy alone efficacy in treating unresectable locally advanced pancreatic cancer","authors":"Ya-Qin Zheng, Rui Huang, Wen-Lu Zou, Chao Liu, H. Niu, J. Yue","doi":"10.1002/pro6.1156","DOIUrl":"https://doi.org/10.1002/pro6.1156","url":null,"abstract":"The prognosis for unresectable locally advanced pancreatic cancer (LAPC) is still poor, and the best therapeutic option is still unknown. The common treatments for LAPC, concurrent chemoradiotherapy (CCRT), 125I seed implantation combined with chemotherapy (125IC), and chemotherapy alone (CA), were studied. In addition, we looked into the impact of radiation dose on the survival of patients receiving chemoradiotherapy.","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45967670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-01Epub Date: 2022-06-11DOI: 10.1002/pro6.1163
Zeyu Zhang, Zhuoran Jiang, Hualiang Zhong, Ke Lu, Fang-Fang Yin, Lei Ren
Objective: Despite its prevalence, cone beam computed tomography (CBCT) has poor soft-tissue contrast, making it challenging to localize liver tumors. We propose a patient-specific deep learning model to generate synthetic magnetic resonance imaging (MRI) from CBCT to improve tumor localization.
Methods: A key innovation is using patient-specific CBCT-MRI image pairs to train a deep learning model to generate synthetic MRI from CBCT. Specifically, patient planning CT was deformably registered to prior MRI, and then used to simulate CBCT with simulated projections and Feldkamp, Davis, and Kress reconstruction. These CBCT-MRI images were augmented using translations and rotations to generate enough patient-specific training data. A U-Net-based deep learning model was developed and trained to generate synthetic MRI from CBCT in the liver, and then tested on a different CBCT dataset. Synthetic MRIs were quantitatively evaluated against ground-truth MRI.
Results: The synthetic MRI demonstrated superb soft-tissue contrast with clear tumor visualization. On average, the synthetic MRI achieved 28.01, 0.025, and 0.929 for peak signal-to-noise ratio, mean square error, and structural similarity index, respectively, outperforming CBCT images. The model performance was consistent across all three patients tested.
Conclusion: Our study demonstrated the feasibility of a patient-specific model to generate synthetic MRI from CBCT for liver tumor localization, opening up a potential to democratize MRI guidance in clinics with conventional LINACs.
{"title":"Patient-specific synthetic magnetic resonance imaging generation from cone beam computed tomography for image guidance in liver stereotactic body radiation therapy.","authors":"Zeyu Zhang, Zhuoran Jiang, Hualiang Zhong, Ke Lu, Fang-Fang Yin, Lei Ren","doi":"10.1002/pro6.1163","DOIUrl":"10.1002/pro6.1163","url":null,"abstract":"<p><strong>Objective: </strong>Despite its prevalence, cone beam computed tomography (CBCT) has poor soft-tissue contrast, making it challenging to localize liver tumors. We propose a patient-specific deep learning model to generate synthetic magnetic resonance imaging (MRI) from CBCT to improve tumor localization.</p><p><strong>Methods: </strong>A key innovation is using patient-specific CBCT-MRI image pairs to train a deep learning model to generate synthetic MRI from CBCT. Specifically, patient planning CT was deformably registered to prior MRI, and then used to simulate CBCT with simulated projections and Feldkamp, Davis, and Kress reconstruction. These CBCT-MRI images were augmented using translations and rotations to generate enough patient-specific training data. A U-Net-based deep learning model was developed and trained to generate synthetic MRI from CBCT in the liver, and then tested on a different CBCT dataset. Synthetic MRIs were quantitatively evaluated against ground-truth MRI.</p><p><strong>Results: </strong>The synthetic MRI demonstrated superb soft-tissue contrast with clear tumor visualization. On average, the synthetic MRI achieved 28.01, 0.025, and 0.929 for peak signal-to-noise ratio, mean square error, and structural similarity index, respectively, outperforming CBCT images. The model performance was consistent across all three patients tested.</p><p><strong>Conclusion: </strong>Our study demonstrated the feasibility of a patient-specific model to generate synthetic MRI from CBCT for liver tumor localization, opening up a potential to democratize MRI guidance in clinics with conventional LINACs.</p>","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ad/88/nihms-1842255.PMC10103741.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9603128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
K. Wong, Katarina Cheng, Saikit Lam, Chenyang Liu, Jing Cai
Nasopharyngeal carcinoma (NPC) is a common malignancy endemic in South‐East Asia. Functional magnetic resonance imaging (fMRI) has been used for prompt detection of treatment response before visible morphological changes in NPC treatment. Among different fMRI techniques, diffusion‐weighted imaging (DWI) and dynamic contrast enhancement (DCE) were proved to be more successful in NPC treatment response assessment whilst the application of magnetic resonance spectroscopy (MRS) remains questionable. Apart from discussing the imaging technique, time points for post‐treatment response assessments are recommended. Four instead of three months is recommended for prompt identification of non‐ or partial responders and 6–9 months post‐treatment multiparametric MRI is also recommended for effective confirmation of complete responding individuals to avoid residual disease. For future advancement, in addition to the post‐treatment response assessment, continuous or longitudinal assessment on the treatment response with the use of magnetic resonance simulator (MR‐simulator) or magnetic resonace imaging guided linear accelerator (MR‐Linac) tailor‐made for radiotherapy (RT) maybe feasible. Longitudinal assessments or predictive radiomics modeling allow spotting out the possibility of treatment failure before the completion or even before the start of treatments. Adaptive instead of salvage treatments can then be prepared, thus reducing the damage and side effects of consecutive cytotoxic treatments.
{"title":"Review of functional magnetic resonance imaging in the assessment of nasopharyngeal carcinoma treatment response","authors":"K. Wong, Katarina Cheng, Saikit Lam, Chenyang Liu, Jing Cai","doi":"10.1002/pro6.1161","DOIUrl":"https://doi.org/10.1002/pro6.1161","url":null,"abstract":"Nasopharyngeal carcinoma (NPC) is a common malignancy endemic in South‐East Asia. Functional magnetic resonance imaging (fMRI) has been used for prompt detection of treatment response before visible morphological changes in NPC treatment. Among different fMRI techniques, diffusion‐weighted imaging (DWI) and dynamic contrast enhancement (DCE) were proved to be more successful in NPC treatment response assessment whilst the application of magnetic resonance spectroscopy (MRS) remains questionable. Apart from discussing the imaging technique, time points for post‐treatment response assessments are recommended. Four instead of three months is recommended for prompt identification of non‐ or partial responders and 6–9 months post‐treatment multiparametric MRI is also recommended for effective confirmation of complete responding individuals to avoid residual disease. For future advancement, in addition to the post‐treatment response assessment, continuous or longitudinal assessment on the treatment response with the use of magnetic resonance simulator (MR‐simulator) or magnetic resonace imaging guided linear accelerator (MR‐Linac) tailor‐made for radiotherapy (RT) maybe feasible. Longitudinal assessments or predictive radiomics modeling allow spotting out the possibility of treatment failure before the completion or even before the start of treatments. Adaptive instead of salvage treatments can then be prepared, thus reducing the damage and side effects of consecutive cytotoxic treatments.","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47389966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Bin Yang, J. Yuan, D. Poon, H. Geng, W. Lam, K. Cheung, S. Yu
We aimed to determine the planning target volume margins applicable to magnetic resonance‐guided stereotactic body radiation therapy (MRgSBRT) of localized prostate cancer on a 1.5 T MR‐Linac.
我们的目的是确定在1.5 T MR - Linac上适用于磁共振引导立体定向放射治疗(MRgSBRT)局部前列腺癌的计划靶体积范围。
{"title":"Assessment of planning target volume margins in 1.5 T magnetic resonance‐guided stereotactic body radiation therapy for localized prostate cancer","authors":"Bin Yang, J. Yuan, D. Poon, H. Geng, W. Lam, K. Cheung, S. Yu","doi":"10.1002/pro6.1155","DOIUrl":"https://doi.org/10.1002/pro6.1155","url":null,"abstract":"We aimed to determine the planning target volume margins applicable to magnetic resonance‐guided stereotactic body radiation therapy (MRgSBRT) of localized prostate cancer on a 1.5 T MR‐Linac.","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"51268979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. M. Chen, L. Qi, R. Cress, Yueju Li, L. Beckett, Baoqing Li
To evaluate how the addition of concurrent chemotherapy to radiation therapy (RT) affects outcomes for Asian American patients with nasopharyngeal carcinoma.
评估在放疗（RT）的基础上同时进行化疗对亚裔美国鼻咽癌患者预后的影响。
{"title":"Effect of radiotherapy and chemotherapy on the survival rate of Asian Americans with nasopharyngeal carcinoma","authors":"A. M. Chen, L. Qi, R. Cress, Yueju Li, L. Beckett, Baoqing Li","doi":"10.1002/pro6.1154","DOIUrl":"https://doi.org/10.1002/pro6.1154","url":null,"abstract":"To evaluate how the addition of concurrent chemotherapy to radiation therapy (RT) affects outcomes for Asian American patients with nasopharyngeal carcinoma.","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47715973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
O. Wong, M. Law, D. Poon, R. W. H. Yung, S. Yu, K. Cheung, J. Yuan
This pilot study explored the use of fast volumetric four‐dimensional magnetic resonance imaging (4D‐MRI) for motion characterization in the abdomen, ultimately aiming for the translation to future MR‐guided radiotherapy (MRgRT) applications.
{"title":"A pilot study of respiratory motion characterization in the abdomen using a fast volumetric 4D‐MRI for MR‐guided radiotherapy","authors":"O. Wong, M. Law, D. Poon, R. W. H. Yung, S. Yu, K. Cheung, J. Yuan","doi":"10.1002/pro6.1153","DOIUrl":"https://doi.org/10.1002/pro6.1153","url":null,"abstract":"This pilot study explored the use of fast volumetric four‐dimensional magnetic resonance imaging (4D‐MRI) for motion characterization in the abdomen, ultimately aiming for the translation to future MR‐guided radiotherapy (MRgRT) applications.","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41569084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Dumas, Marisa Leney, Joshua Kim, P. Sevak, M. Elshaikh, M. Pantelic, B. Movsas, I. Chetty, N. Wen
To assess the feasibility of using synthetic computed tomography for treatment planning of the dominant intraprostatic lesion (DIL), a high‐risk region of interest that offers potential for increased local tumor control.
{"title":"Magnetic resonance imaging‐only‐based radiation treatment planning for simultaneous integrated boost of multiparametric magnetic resonance imaging‐defined dominant intraprostatic lesions","authors":"M. Dumas, Marisa Leney, Joshua Kim, P. Sevak, M. Elshaikh, M. Pantelic, B. Movsas, I. Chetty, N. Wen","doi":"10.1002/pro6.1152","DOIUrl":"https://doi.org/10.1002/pro6.1152","url":null,"abstract":"To assess the feasibility of using synthetic computed tomography for treatment planning of the dominant intraprostatic lesion (DIL), a high‐risk region of interest that offers potential for increased local tumor control.","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43138158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rectal cancer is one of the most common malignant tumors. In China, rectal cancer has been the third most frequently diagnosed cancer and the fifth leading cause of cancer death, with changes of residents’ lifestyle factors and diets. The best treatment for rectal cancer depends on many factors. Multidisciplinary Treatment has become the basis for improving the therapeutic effect, in which radiology is increasingly necessary for treating patients with rectal cancer. For patients who have extensive, fixed, bulky tumors or obvious nodal disease, radiotherapy and chemotherapy combined with surgery has emerged as the standard of care. For patients with metastatic disease, the reasonable combination of local and systemic therapy might be an alternative. Improvements in imaging, pathological diagnosis and radiation techniques provide a solid foundation for promoting the level of clinical practice in rectal cancer. High‐quality magnetic resonance imaging distinguishing risk stratification, molecular markers predicting therapeutic effect and prognosis, magnetic resonance imaging in delineating target volumes drawn, intensity‐modulated radiation therapy, and image‐guides radiation therapy for precision treatment delivery are all being widely applied in multiple centers. Furthermore, as the role of targeted therapy and immune therapy has become increasingly prominent, the attempt of combined radiotherapy is also ongoing. In view of the characteristics and current situation of diagnosis and treatment of rectal cancer in China, the guidelines will present the basis and reference for combined treatment and standardized treatments. Meanwhile, there may be continuous new advances in clinical practice, and that will be a new basis to update the guidelines, directly benefiting all rectal cancer patients and facilitating discipline developments.
{"title":"Radiotherapy guidelines for rectal cancer in China (2020 Edition)","authors":"Shixin Liu, Jing Jin","doi":"10.1002/pro6.1141","DOIUrl":"https://doi.org/10.1002/pro6.1141","url":null,"abstract":"Rectal cancer is one of the most common malignant tumors. In China, rectal cancer has been the third most frequently diagnosed cancer and the fifth leading cause of cancer death, with changes of residents’ lifestyle factors and diets. The best treatment for rectal cancer depends on many factors. Multidisciplinary Treatment has become the basis for improving the therapeutic effect, in which radiology is increasingly necessary for treating patients with rectal cancer. For patients who have extensive, fixed, bulky tumors or obvious nodal disease, radiotherapy and chemotherapy combined with surgery has emerged as the standard of care. For patients with metastatic disease, the reasonable combination of local and systemic therapy might be an alternative. Improvements in imaging, pathological diagnosis and radiation techniques provide a solid foundation for promoting the level of clinical practice in rectal cancer. High‐quality magnetic resonance imaging distinguishing risk stratification, molecular markers predicting therapeutic effect and prognosis, magnetic resonance imaging in delineating target volumes drawn, intensity‐modulated radiation therapy, and image‐guides radiation therapy for precision treatment delivery are all being widely applied in multiple centers. Furthermore, as the role of targeted therapy and immune therapy has become increasingly prominent, the attempt of combined radiotherapy is also ongoing. In view of the characteristics and current situation of diagnosis and treatment of rectal cancer in China, the guidelines will present the basis and reference for combined treatment and standardized treatments. Meanwhile, there may be continuous new advances in clinical practice, and that will be a new basis to update the guidelines, directly benefiting all rectal cancer patients and facilitating discipline developments.","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49473368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yung Lee, Y. Samarasinghe, Nadeesha Samarasinghe, Janhavi Patel, T. McKechnie, C. Finley, W. Hanna, A. Swaminath, J. Agzarian
While pulmonary metastases are often managed through metastasectomies, stereotactic body radiation therapy (SBRT) is a relatively novel treatment that has shown promise for this disease. This review aimed to summarize the current findings of SBRT in the treatment of pulmonary metastases. MEDLINE, EMBASE, and CENTRAL were searched for articles that examined the use of SBRT for patients with pulmonary metastases. Primary outcomes included overall survival, disease‐free survival, and progression‐free survival. Results were pooled where appropriate. Risk of bias was assessed through the Methodological Index for Non‐Randomized Studies tool. After screening, 13 studies with 545 patients conducted between 2006 and 2020 were included in this review. Primary tumor localizations included gastrointestinal, pulmonary, and bone, among others. Pooled overall survival at 1 year was 81%, 41% at 3 years, 34% at 4 years, and 26% at 5 years. Pooled progression‐free survival at 1, 2, and 3 years was 60%, 41%, and 31% respectively. Local control at 1, 2, and 3 years were 90%, 79%, and 77%, respectively. Preliminary evidence regarding SBRT for treatment of pulmonary metastases shows promising benefits for overall survival and local control. Further high‐quality prospective trials are required to investigate the effectiveness and treatment‐related adverse effects of SBRT, and should compare it with metastasectomy.
{"title":"The role of stereotactic body radiation therapy in the management of pulmonary metastases: a systematic review","authors":"Yung Lee, Y. Samarasinghe, Nadeesha Samarasinghe, Janhavi Patel, T. McKechnie, C. Finley, W. Hanna, A. Swaminath, J. Agzarian","doi":"10.1002/pro6.1148","DOIUrl":"https://doi.org/10.1002/pro6.1148","url":null,"abstract":"While pulmonary metastases are often managed through metastasectomies, stereotactic body radiation therapy (SBRT) is a relatively novel treatment that has shown promise for this disease. This review aimed to summarize the current findings of SBRT in the treatment of pulmonary metastases. MEDLINE, EMBASE, and CENTRAL were searched for articles that examined the use of SBRT for patients with pulmonary metastases. Primary outcomes included overall survival, disease‐free survival, and progression‐free survival. Results were pooled where appropriate. Risk of bias was assessed through the Methodological Index for Non‐Randomized Studies tool. After screening, 13 studies with 545 patients conducted between 2006 and 2020 were included in this review. Primary tumor localizations included gastrointestinal, pulmonary, and bone, among others. Pooled overall survival at 1 year was 81%, 41% at 3 years, 34% at 4 years, and 26% at 5 years. Pooled progression‐free survival at 1, 2, and 3 years was 60%, 41%, and 31% respectively. Local control at 1, 2, and 3 years were 90%, 79%, and 77%, respectively. Preliminary evidence regarding SBRT for treatment of pulmonary metastases shows promising benefits for overall survival and local control. Further high‐quality prospective trials are required to investigate the effectiveness and treatment‐related adverse effects of SBRT, and should compare it with metastasectomy.","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43628990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：